Description: IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; cartilage assays for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides services, such as filling and lyophilization for making disposable medical device components; and custom fermentation and micro dispensing of enzymes, as well as contract manufacturing. It serves manufacturers of medical devices, quality control labs, and academic research institutions. The company was founded in 1986 and is based in Montreal, Canada.
Home Page: www.ibex.ca
5485 Rue Pare
Montreal,
QC
H4P 1P7
Canada
Phone:
514 344 4004
Officers
| Name | Title |
|---|---|
| Mr. Paul Baehr | Pres, CEO & Chairman |
| Belinda Franco C.A., CPA | CFO, VP of Fin. & Admin. and Sec. |
| Mahendra Kumar Pallapothu | VP of Operations |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 11.006 |
| Price-to-Book MRQ: | 1.4863 |
| Price-to-Sales TTM: | 1.1305 |
| IPO Date: | |
| Fiscal Year End: | July |
| Full Time Employees: | 0 |